MCHI vs XBI
iShares MSCI China ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.59% for MCHI.
- • MCHI pays a higher dividend yield (2.14%).
Side-by-side metrics
| Metric | MCHI | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.59% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.14% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $5.89B | $10.73B |
YTD return | -11.44% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.59 | 1.10 |
P/E ratio | 11.88 | — |
Last price | $53.17 | $164.01 |
Inception | — | — |
Issuer | iShares | State Street |
MCHI top holdings
| 0700.HK | Tencent Holdings Ltd | 14.21% |
| 9988.HK | Alibaba Group Holding Ltd Ordinary Shares | 8.35% |
| 00939 | China Construction Bank Corp Class H | 3.65% |
| 01398 | Industrial And Commercial Bank Of China Ltd Class H | 2.25% |
| 1810.HK | Xiaomi Corp Class B | 1.99% |
| 9999.HK | NetEase Inc Ordinary Shares | 1.91% |
| 3690.HK | Meituan Class B | 1.85% |
| PDD | PDD Holdings Inc ADR | 1.82% |
| 03988 | Bank Of China Ltd Class H | 1.80% |
| 02318 | Ping An Insurance (Group) Co. of China Ltd Class H | 1.79% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About MCHI
MCHI (iShares MSCI China ETF) is Broad China equity exposure. Managed by iShares, the fund carries $5.9B in assets under management, an expense ratio of 0.59%, a dividend yield of 2.14%. Its largest holding is Tencent Holdings Ltd (0700.HK), which represents 14.2% of the portfolio. Real Estate is the fund's largest sector exposure at 1.5%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.